title: Ranolazine CV Therapeutics.
abstract: CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a partial fatty acid oxidation inhibitor, for the potential treatment of angina and acute coronary syndromes. By October 2004, enrollment in the phase III MERLIN TIMI-36 study was ongoing and the company anticipated completion by the end of the first quarter of 2005.
authors.affiliation: University of Siena, Postgraduate School of Cardiology, Policlinico Le Scotte, Viale Bracci 74, 53100 Siena, Italy. marzilli@unisi.it
authors.forename: Mario
authors.initials: M
authors.lastname: Marzilli
mesh_terms: D000083:Acetanilides; D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015394:Molecular Structure; D010879:Piperazines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000069458:Ranolazine
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine